The prospects and limitations of liquid biopsy utilization for clinical practice in Taiwan
Physicians are generally less inclined to replace tissue biopsies with liquid biopsy, but hematologic oncologists show more flexibility. Test brand plays a role in physician decision-making, and the inclusion of liquid biopsy under NHI coverage is vital for its broader adoption in Taiwan.
Authors
- Huei-Ying Li
- Chi‐Yuan Yao (ORCID: https://orcid.org/0000-0001-5052-9445)
- Chia‐Hsun Hsieh (ORCID: https://orcid.org/0000-0002-5547-409X)
- Shao-Hsuan Chang (ORCID: https://orcid.org/0000-0003-4136-7928)
- C.L. Chang
- Yu-Hsuan Yang
Institutions
- National Taiwan University (TW)
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
- National Taiwan University Hospital (TW)
Publication Details
- Journal
- The Journal of Liquid Biopsy
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.jlb.2025.100290
- Citations
- 3
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 2.81